BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sifrol/Mirapex (Pramipexole) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sifrol/Mirapex (Pramipexole)\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06269146-1759@assetmemo.bio
DTSTAMP:20261121T005811Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Sifrol/Mirapex (Pramipexole): Phase 2 readout est. (NCT06269146)
DESCRIPTION:Sifrol/Mirapex (Pramipexole)\, phase 2.\nStudy: Pramipexole to 
 Enhance Social Connections\nEstimated primary completion: November 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pramipexole#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06269146
URL:https://assetmemo.bio/drug/pramipexole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06611592-1759@assetmemo.bio
DTSTAMP:20261121T005811Z
DTSTART;VALUE=DATE:20280820
DTEND;VALUE=DATE:20280821
SUMMARY:Sifrol/Mirapex (Pramipexole): Phase 2 readout est. (NCT06611592)
DESCRIPTION:Sifrol/Mirapex (Pramipexole)\, phase 2.\nStudy: Safety and Effi
 cacy of Pramipexole Treatment in Resistant Obsessive-Compulsive Disorder (
 OCD)\nEstimated primary completion: 20 August 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pramipexole#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06611592
URL:https://assetmemo.bio/drug/pramipexole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06580041-1759@assetmemo.bio
DTSTAMP:20261121T005811Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Sifrol/Mirapex (Pramipexole): Phase 4 readout est. (NCT06580041)
DESCRIPTION:Sifrol/Mirapex (Pramipexole)\, phase 4.\nStudy: Precision Care 
 for Major Depressive Disorder\nEstimated primary completion: 1 September 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pramipexole#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06580041
URL:https://assetmemo.bio/drug/pramipexole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07664852-1759@assetmemo.bio
DTSTAMP:20261121T005811Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Sifrol/Mirapex (Pramipexole): Phase 3 readout est. (NCT07664852)
DESCRIPTION:Sifrol/Mirapex (Pramipexole)\, phase 3.\nStudy: Pramipexole vs 
 Placebo Treatment in Bipolar Disorder With Anhedonic Depression\nEstimated
  primary completion: 31 December 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pramipexole#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07664852
URL:https://assetmemo.bio/drug/pramipexole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07022405-1759@assetmemo.bio
DTSTAMP:20261121T005811Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Sifrol/Mirapex (Pramipexole): Phase 2 readout est. (NCT07022405)
DESCRIPTION:Sifrol/Mirapex (Pramipexole)\, phase 2.\nStudy: Stratified Phar
 macological Approaches for Regulating Circuit-Level Effects\nEstimated pri
 mary completion: August 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pramipexole#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07022405
URL:https://assetmemo.bio/drug/pramipexole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
